摘要:近日,生物医药行业一桩标志性授权合作正式官宣:君实生物将自研IL-17A单抗偌考奇拜单抗(JS005)大中华区全链条权益,独家授予复星医药旗下复星万邦。
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.